GSK plc (LSE/NYSE: GSK) and Aiolos Bio, Inc. (Aiolos) have announced a significant agreement, where GSK will acquire Aiolos, a clinical-stage biopharmaceutical company focusing on respiratory and inflammatory conditions. The acquisition, valued at $1 billion upfront and potential regulatory milestone payments of up to $400 million, signifies GSK’s commitment to addressing the unmet needs of […]
GSK plc has unveiled positive outcomes from the DREAMM-7 head-to-head phase III trial, evaluating Blenrep (belantamab mafodotin) as a treatment for relapsed or refractory multiple myeloma. This pivotal trial demonstrated a statistically significant progression-free survival (PFS) benefit for Blenrep combined with bortezomib and dexamethasone (BorDex) against the daratumumab plus BorDex regimen. Trial Details and Efficacy […]
Global pharmaceutical titan GSK plc is teaming up with Chongqing Zhifei Biological Products, Ltd. (Zhifei) – China’s leading vaccine revenue generator – to co-promote its groundbreaking shingles vaccine, Shingrix, across the vast Chinese terrain. This exclusive three-year collaboration, beginning 1 January 2024, is set to be a game-changer in elevating patient access to Shingrix. There’s […]
ViiV Healthcare, majorly owned by GSK with Pfizer and Shionogi as shareholders, announced that the European Commission (EC) has authorized Apretude, also known as cabotegravir long-acting (LA) injectable and tablets, for HIV prevention. This revolutionary treatment is now the only approved HIV prevention option in the European Union that offers an alternative to 365 daily […]
GSK has agreed to acquire BELLUS Health, a Canadian biopharma company, in a deal worth around $2 billion in a move to further bolster its specialty medicines and respiratory pipeline. The deal gives GSK access to a late-stage P2X3 antagonist called camlipixant, which is intended for the treatment of refractory chronic cough (RCC). Presently, camlipixant […]
Biopharma company GSK has secured the full approval of the US Food and Drug Administration (FDA) for its Jemperli (dostarlimab-gxly) drug for recurrent or advanced mismatch repair-deficient endometrial cancer. Jemperli is indicated for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has advanced or after a prior platinum-containing […]
GSK has secured the approval of the US Food and Drug Administration (FDA) for the company’s Jesduvroq (daprodustat) for anaemia of chronic kidney disease (CKD) in adults on dialysis. Jesduvroq is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor indicated for the daily once treatment of anaemia due to CKD in adults on dialysis for at […]
Wave Life Sciences and GSK have forged a partnership to discover and develop oligonucleotide therapeutics, focusing on new genetic targets, for respiratory diseases. The discovery collaboration with an initial four-year research term is expected to advance Wave Life Sciences’ preclinical RNA editing program, WVE-006, to treat alpha-1 antitrypsin deficiency (AATD), a disease that impacts the […]
GlaxoSmithKline (GSK) has agreed to acquire Affinivax, a Boston-based clinical-stage vaccine developer, in a deal worth up to $3.3 billion. The consideration includes an upfront payment of $2.1 billion and payments of up to $1.2 billion based on potential development milestones. Affinivax is engaged in developing vaccines by using its Multiple Antigen Presenting System (MAPS) […]
GlaxoSmithKline (GSK) has agreed to acquire Sierra Oncology, a California-based biopharma company, in a deal worth around $1.9 billion (£1.5 billion). As per the terms of the deal, shareholders of the publicly-listed Sierra Oncology will be paid $55 per share in cash. Sierra Oncology is engaged in developing targeted therapies for the treatment of rare […]